



**THE STABLE
AAV PRODUCER
CELL LINES**

ELECTA®
UNLOCKS THE FULL POTENTIAL
OF GENE THERAPIES

Gene therapy is more and more considered to be the most effective and often only treatment option for many severe and life-threatening diseases. And as gene therapy is moving towards more common indications with larger patient numbers and systemic treatments larger amounts of vector materials are required. Consequently, production processes are needed that are fit for this purpose, meeting the demand for necessary quantities of viral vectors with high yields and consistent qualities.

ELECTA® addresses this urgent need by enabling viral vector manufacturing from stable producer cells in an industry-standard, scalable suspension format.

electa®

ELEVATING
VECTOR
MANUFACTURING
TO THE NEXT LEVEL

ELECTA® STABLE AAV PRODUCER CELL LINES

CEVEC's ELECTA® technology takes viral vector manufacturing to the next level. Through a unique producer cell line approach, ELECTA® enables high-performance AAV vector production. The technology delivers consistent quality in all types and formats of suspension bioreactors up to large scale production. No need for helper viruses, expensive transfection reagents or cGMP-grade plasmids. Just propagate your producer cells and switch on production.

Start producing AAV. From day one in a robust, reliable and fully scalable format.

ELECTA® PREMIUM TECHNOLOGY FOR PREMIUM THERAPIES



STABLE PRODUCER CELLS

All components for AAV production stably integrated into one producer cell

CONSISTENT QUALITY

Consistent AAV quality across batches – no transfection steps

FULL SCALABILITY

Scaling up from shake flask to large scale bioreactor without drop in productivity

ROBUST PROCESS

Reliable AAV production in suspension bioreactors and serum-free media

ELECTA®


YOUR TAILOR-MADE PRODUCER CELL LINE

The **ELECTA® Producer Cell Line** is custom-made based on your AAV vector design by stably incorporating the sequences of the serotype-specific capsid and the gene of interest into the genome of the cell. It is the perfect cell line for reliable AAV production in suspension bioreactors at all scales and formats. Available as a research cell bank or, optionally, as a fully tested GMP Master Cell Bank (MCB) for

the manufacturing of clinical and commercial material. All producer cell lines are derived from the monoclonal **ELECTA® Alpha Cell Line** which provides helper functions, replicase and further genetic elements necessary to generate stable ELECTA® Producer Cell Lines and to produce AAV vector material at consistent yield and quality.



Stable Producer Cell Line



ELECTA® PACKAGES

STARTER PACKAGE

The **ELECTA® Starter Package** is the ideal starting point for a fast supply of AAV vector material for preclinical research and early clinical stages. It is compatible with all common serotypes and any engineered capsids. Being based on the ELECTA® Alpha Cell Line, you can easily upgrade to the ELECTA® Product Package. Use the same platform for all clinical phases and up to commercial manufacturing. No need to switch your AAV production system again.

PRODUCT PACKAGE


The **ELECTA® Product Package** is specifically designed to provide a customized service package from gene sequence to GMP production for your dedicated individual AAV gene therapy vector. We design and develop your producer cell line. If required, we can provide you with a fully tested MCB, a complete process package and regulatory documentation. Get full control over your AAV manufacturing process with your custom-made ELECTA® Producer Cell Line.

PARTNER PACKAGE

The **ELECTA® Partner Package** specifically enables Pharma and Biotech companies to make use of the ELECTA® technology across their entire portfolio of AAV-based gene therapy programs. Besides a license to the ELECTA® platform, CEVEC offers cell line development services, technical training modules and regulatory support as needed. Benefit from a preferred and flexible access to the full potential of the ELECTA® technology.

ELEVECTA®


INNOVATION FROM EARLY RESEARCH TO COMMERCIALIZATION



The ELEVECTA® technology covers all aspects of AAV production, from fast and early access to vector material for research and exploratory studies, up to large scale manufacturing. The technology can be implemented in any modern process development or manufacturing facility running standard suspension bioreactors.

The broad range of entry points to the ELEVECTA® technology is reflected in the different package offerings that have been designed to match our customers' needs. Choose your technology access point and expand from there. No matter where you start: You will never have to change your AAV production technology again.

	ELEVECTA® STARTER PACKAGE	ELEVECTA® PRODUCT PACKAGE	ELEVECTA® PARTNER PACKAGE
BEST SUITED FOR	Pharma & Biotech with gene therapy programs in early stage	Pharma & Biotech with a specific gene therapy program	Pharma with a portfolio of gene therapy programs
DEVELOPMENT STAGE	Research / Preclinical	Preclinical / Early clinical	All development stages
APPLICABLE SCALES	Lab scale	Lab scale to commercial scale	Lab scale to commercial scale
SERVICES INCLUDED	<ul style="list-style-type: none"> - Fast access to AAV research material while vector design is finalized - Process development support - Analytical support 	<ul style="list-style-type: none"> - Producer cell line development for specific program - Process development support - Analytical support - GMP MCB/WCB, including release testing - Regulatory documentation 	<ul style="list-style-type: none"> - Producer cell line development for multiple programs - Process development support - Analytical support - GMP MCB/WCB, including release testing - Regulatory documentation - Technology transfer & training modules
USE OF PRODUCTS	Research use	Clinical development and commercialization	Clinical development and commercialization
LICENSE	-	Individual gene therapy program	Multiple gene therapy programs



CEVEC is a leading provider of high-performance cell technology for the manufacturing of advanced biotherapeutics from R&D to manufacturing scale, including modern gene therapy vectors and complex recombinant proteins.

For further information please contact:

CEVEC Pharmaceuticals GmbH
Gottfried-Hagen-Str. 60-62 | 51105 Köln | Germany
Phone +49 221 46020800 | E-Mail info@cevec.com

www.cevec.com